Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

ORIC Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

HIGHLY DIFFERENTIATED 1L PRELIMINARY SYSTEMIC ACTIVITY OF 67% ORR AND 100% INTRACRANIAL ORR (BY BICR-RANO), INCLUDING IN PATIENTS WITH ACTIVE BRAIN METASTASES

ORIC PHARMACEUTICALS PRESENTS POTENTIAL BEST-IN-CLASS PROFILE FOR ENOZERTINIB WITH ROBUST SYSTEMIC AND CNS ACTIVITY IN 1L AND 2L NSCLC PATIENTS WITH EGFR EXON 20 MUTATIONS AT THE ESMO ASIA CONGRESS 2025

SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, DEC. 05, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, INC. (NASDAQ:ORIC), A CLINICAL STAGE ONCOLOGY COMPANY FOCUSED ON DEVELOPING TREATMENTS THAT ADDRESS MECHANISMS OF THERAPEUTIC RESISTANCE, TODAY ANNOUNCED THAT ON DECEMBER 1, 2025 (THE GRANT DATE), ORIC GRANTED A TOTAL OF 69,200 NON-QUALIFIED STOCK OPTIONS AND 11,400 RESTRICTED STOCK UNITS TO THREE NEW NON-EXECUTIVE EMPLOYEES WHO BEGAN THEIR EMPLOYMENT WITH ORIC IN NOVEMBER 2025.

ORIC PHARMACEUTICALS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

SYSTEMIC ACTIVITY OF 35% ORR IN 2L+ PATIENTS, INCLUDING IN PATIENTS WITH ACTIVE BRAIN METASTASES MANAGEABLE SAFETY PROFILE WITH LOW DISCONTINUATION RATE ENROLLMENT COMPLETED; NO FURTHER DEVELOPMENT PLANNED IN THIS PATIENT POPULATION COMPANY TO HOST A CONFERENCE CALL AND WEBCAST ON SATURDAY, DECEMBER 6, 2025, AT 8:00 PM ET SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, DEC. 05, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, INC. (NASDAQ: ORIC), A CLINICAL STAGE ONCOLOGY COMPANY FOCUSED ON DEVELOPING TREATMENTS THAT ADDRESS MECHANISMS OF THERAPEUTIC RESISTANCE, ANNOUNCED DATA FROM A PHASE 1B TRIAL OF ENOZERTINIB (ORIC-114) AT THE ESMO ASIA CONGRESS 2025.

ORIC PHARMACEUTICALS PRESENTS ENOZERTINIB DATA IN NSCLC PATIENTS WITH HER2 EXON 20 MUTATIONS AT THE ESMO ASIA CONGRESS 2025

HIGHLY DIFFERENTIATED 1L EGFR PACC PRELIMINARY SYSTEMIC ACTIVITY OF 80% ORR AND 100% INTRACRANIAL ORR, INCLUDING IN PATIENTS WITH ACTIVE BRAIN METASTASES

ORIC PHARMACEUTICALS PRESENTS POTENTIAL BEST-IN-CLASS PROFILE FOR ENOZERTINIB WITH ROBUST SYSTEMIC AND CNS ACTIVITY IN 1L AND PREVIOUSLY TREATED NSCLC PATIENTS WITH EGFR ATYPICAL MUTATIONS AT THE ESMO ASIA CONGRESS 2025

COMPANY TO HOST A CONFERENCE CALL AND WEBCAST ON SATURDAY, DECEMBER 6, 2025, AT 8:00 PM ET COMPANY TO HOST A CONFERENCE CALL AND WEBCAST ON SATURDAY, DECEMBER 6, 2025, AT 8:00 PM ET

ORIC PHARMACEUTICALS ANNOUNCES ENOZERTINIB (ORIC-114) LATE-BREAKING ORAL PRESENTATIONS IN EGFR ATYPICAL AND EGFR EXON 20 NSCLC AT THE ESMO ASIA CONGRESS 2025

SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, DEC. 01, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, INC. (NASDAQ: ORIC), A CLINICAL STAGE ONCOLOGY COMPANY FOCUSED ON DEVELOPING TREATMENTS THAT ADDRESS MECHANISMS OF THERAPEUTIC RESISTANCE, TODAY ANNOUNCED A POSTER PRESENTATION HIGHLIGHTING DATA FROM A PHASE 1B TRIAL OF ENOZERTINIB (ORIC-114) AT THE ESMO ASIA CONGRESS 2025 TAKING PLACE DECEMBER 5-7, 2025 IN SINGAPORE.

ORIC PHARMACEUTICALS ANNOUNCES ENOZERTINIB (ORIC-114) POSTER PRESENTATION IN HER2 EXON 20 NSCLC AT THE ESMO ASIA CONGRESS 2025

SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, NOV. 24, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, INC. (NASDAQ: ORIC), A CLINICAL STAGE ONCOLOGY COMPANY FOCUSED ON DEVELOPING TREATMENTS THAT ADDRESS MECHANISMS OF THERAPEUTIC RESISTANCE, TODAY ANNOUNCED THAT MANAGEMENT WILL BE PARTICIPATING IN A FIRESIDE CHAT AT THE 8TH ANNUAL EVERCORE HEALTHCARE CONFERENCE ON WEDNESDAY, DECEMBER 3, 2025, AT 11:15 A.M. ET. MANAGEMENT WILL ALSO BE PARTICIPATING IN ONE-ON-ONE MEETINGS.

ORIC PHARMACEUTICALS TO PARTICIPATE IN THE 8TH ANNUAL EVERCORE HEALTHCARE CONFERENCE

ANNOUNCED COMPLETION OF DOSE EXPLORATION PORTION OF ORIC-944 PHASE 1B CLINICAL TRIAL AND PRESENTED DATA THAT CONTINUES TO DEMONSTRATE POTENTIAL BEST-IN-CLASS EFFICACY AND SAFETY

ORIC PHARMACEUTICALS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CLINICAL AND OPERATIONAL UPDATES

EFFICACY DATA REMAIN CONSISTENT WITH PRIOR DISCLOSURE AND CONTINUE TO DEMONSTRATE BROAD AND DEEP PSA RESPONSES, WITH 55% PSA50 RESPONSE RATE AND 20% PSA90 RESPONSE RATE RAPID AND DEEP CTDNA REDUCTIONS WERE OBSERVED IN 76% OF PATIENTS AND CTDNA CLEARANCE WAS OBSERVED IN 59% OF PATIENTS, UNDERSCORING POTENTIAL FOR LONG-TERM TREATMENT AND SURVIVAL BENEFIT PSA RESPONSES AND CTDNA REDUCTIONS WERE OBSERVED ACROSS ALL ORIC-944 DOSE LEVELS AND AT COMPARABLE RATES IN COMBINATION WITH APALUTAMIDE OR WITH DAROLUTAMIDE BOTH COMBINATION REGIMENS CONTINUE TO DEMONSTRATE A SAFETY AND TOLERABILITY PROFILE COMPATIBLE WITH LONG-TERM DOSING, WITH THE VAST MAJORITY OF ADVERSE EVENTS GRADE 1 OR 2 AND CONSISTENT WITH PRC2 AND AR INHIBITION SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, NOV. 13, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, INC. (NASDAQ: ORIC), A CLINICAL STAGE ONCOLOGY COMPANY FOCUSED ON DEVELOPING TREATMENTS THAT ADDRESS MECHANISMS OF THERAPEUTIC RESISTANCE, TODAY ANNOUNCED ADDITIONAL EFFICACY AND SAFETY DATA FROM THE PHASE 1B TRIAL OF ONCE DAILY ORIC-944 IN COMBINATION WITH ANDROGEN RECEPTOR (AR) INHIBITORS IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC).

ORIC PHARMACEUTICALS ANNOUNCES COMPLETION OF DOSE EXPLORATION PORTION OF ORIC-944 PHASE 1B CLINICAL TRIAL AND CONTINUES TO DEMONSTRATE POTENTIAL BEST-IN-CLASS EFFICACY AND SAFETY

SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, NOV. 07, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, INC. (NASDAQ:ORIC), A CLINICAL STAGE ONCOLOGY COMPANY FOCUSED ON DEVELOPING TREATMENTS THAT ADDRESS MECHANISMS OF THERAPEUTIC RESISTANCE, TODAY ANNOUNCED THAT ON NOVEMBER 3, 2025 (THE GRANT DATE), ORIC GRANTED A TOTAL OF 18,400 NON-QUALIFIED STOCK OPTIONS AND 3,000 RESTRICTED STOCK UNITS TO ONE NEW NON-EXECUTIVE EMPLOYEE WHO BEGAN THEIR EMPLOYMENT WITH ORIC IN OCTOBER 2025.

SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, NOV. 06, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, INC. (NASDAQ: ORIC), A CLINICAL STAGE ONCOLOGY COMPANY FOCUSED ON DEVELOPING TREATMENTS THAT ADDRESS MECHANISMS OF THERAPEUTIC RESISTANCE, TODAY ANNOUNCED THE PUBLICATION OF A PEER-REVIEWED RESEARCH PAPER IN CANCER RESEARCH, A JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH.

ORIC PHARMACEUTICALS ANNOUNCES PUBLICATION IN CANCER RESEARCH ON THE DISCOVERY AND DEVELOPMENT OF ENOZERTINIB, A HIGHLY SELECTIVE, BRAIN-PENETRANT EGFR INHIBITOR

SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, NOV. 04, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, INC. (NASDAQ: ORIC), A CLINICAL STAGE ONCOLOGY COMPANY FOCUSED ON DEVELOPING TREATMENTS THAT ADDRESS MECHANISMS OF THERAPEUTIC RESISTANCE, TODAY ANNOUNCED THAT MANAGEMENT WILL BE PARTICIPATING IN THE FOLLOWING INVESTOR CONFERENCES IN NOVEMBER:

ORIC PHARMACEUTICALS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, OCT. 27, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, INC. (NASDAQ: ORIC), A CLINICAL STAGE ONCOLOGY COMPANY FOCUSED ON DEVELOPING TREATMENTS THAT ADDRESS MECHANISMS OF THERAPEUTIC RESISTANCE, PRESENTED POSTERS AT THE 2025 EORTC-NCI-AACR INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS HIGHLIGHTING PRECLINICAL DATA THAT FURTHER ILLUSTRATE THE POTENTIAL FOR ORIC-944, A POTENT AND SELECTIVE ALLOSTERIC INHIBITOR OF THE POLYCOMB REPRESSIVE COMPLEX 2 (PRC2) VIA THE EMBRYONIC ECTODERM DEVELOPMENT (EED) SUBUNIT, TO TREAT PROSTATE CANCER AND VARIOUS OTHER SOLID TUMORS.

ORIC PHARMACEUTICALS PRESENTED PRECLINICAL DATA AT THE EORTC-NCI-AACR INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS SUPPORTING BEST-IN-CLASS POTENTIAL OF ORIC-944 TO TREAT PATIENTS WITH PROSTATE CANCER AND OTHER SOLID TUMORS

ORIC Pharmaceuticals, Inc.

ORIC

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ORIC Pharmaceuticals, Inc.

ORIC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ORIC